-- Partners to Generate Novel Bispecific Antibodies Directed Toward an Anti-tumor Target Identified by Astellas -- -- Astellas to Receive Exclusive Worldwide License to Potential Drug Candidates -- MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 2, 2019-- Xencor, Inc.

MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 1, 2019-- Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will

MONROVIA, Calif. --(BUSINESS WIRE)--Mar. 8, 2019-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced the closing of its research

- Initial Data from Phase 1 Study of XmAb®14045 Presented at ASH 2018; Multiple Complete Remissions Achieved in Advanced AML Patient Population; Study on Partial Clinical Hold Pending Resolution with FDA - - Research and License Agreement for XmAb®24306 and IL-15 Cytokines Provides $120 Million

MONROVIA, Calif. , Feb. 20, 2019 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the U.S.

MONROVIA, Calif. , Feb. 19, 2019 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it will release fourth

MONROVIA, Calif. , Feb. 7, 2019 /PRNewswire/ --  Xencor, Inc.  (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will

-- Xencor Receives $120 Million Upfront Payment, up to $180 Million in Development Milestones Per Program and Profit Share from Commercialized Medicines MONROVIA, Calif. , Feb. 5, 2019 /PRNewswire/ --  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered

-- Initial data from the ongoing Phase 1 study in patients with B-cell malignancies expected in 2019 -- -- Xencor and Novartis to continue co-developing XmAb®14045, a CD123 x CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia -- MONROVIA, Calif. , Jan.

MONROVIA, Calif. , Dec. 3, 2018 /PRNewswire/ --  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced initial data from its ongoing Phase 1